Skip to main content
. 2017 Oct 17;35(36):4003–4011. doi: 10.1200/JCO.2017.75.8177

Fig A4.

Fig A4.

Moderate-severe chronic graft-versus-host disease–free survival by arm in each conditioning regimen. (A) Cyclophosphamide and total body irradiation (Cy-TBI). (B) Busulfan and cyclophosphamide (Bu-Cy). (C) Busulfan and fludarabine (Bu-Flu). Log-rank test was used for group comparisons. ATLG, anti–T-lymphocyte globulin.